Combining Restylane Skinboosters and Sculptra may produce progressive and meaningful improvements in skin quality, especially hydration, on the face and the décolletage of women in menopause, according to interim results from a nine‑month clinical sequencing investigator-initiated trial (IIT).
Restylane Skinboosters (Galderma), tiny droplets of hyaluronic acid injected just below the skin’s surface, drive faster extra-cellular matrix and elastin-associated effects to deliver hydration and improvements in skin roughness, fine lines, and other imperfections. Sculptra (Galderma), a biostimulatory injectable containing poly-L-lactic acid (PLLA), boosts collagen across all three skin layers.
Facial hydration and measures of skin‑barrier function improved over time in both groups, and the improvements were mirrored by patient‑reported outcomes, with satisfaction scores rising consistently across the study and reaching high levels by Month 6.
“This first-of-its-kind clinical study is helping address an important unmet need by generating objective data in a population that has historically been overlooked in aesthetic research,” says Study Investigator Andreas Nikolis, MD, PhD, FRCSC, an Associate Professor of Plastic Surgery at McGill University in Montreal, Quebec, Canada, in a news release. “The interim findings are highly encouraging, demonstrating meaningful improvements in skin hydration and collagen-related skin quality over time. Equally important, these measurable clinical benefits are mirrored by rising patient satisfaction throughout the study. For clinicians, these early results offer valuable evidence-based insight into how we can better support aging menopausal patients with treatment strategies that are tailored to the biologic changes of this stage of life.”
Neither product is approved for these indications in the US.